The Presidencies’ perspective on the pharmaceutical strategy: Europe’s to-do list on access to medicinesEPHA #A2MDialogues
25 November 2020
Our fourth dialogue in a series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.
Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.
Following the publication of the EU’s Pharmaceutical Strategy by the European Commission, senior representatives of the upcoming EU Presidencies (Portugal & Slovenia) and the Netherlands offer their perspective on what should be prioritised and debate next steps in European pharmaceutical policy.
Rui Ivo Santos
Slovenian Medicines Agency
Marcel van Raaij
Medicines & Medical Technologies
Dutch Ministry of Health
Policy Manager, Universal Access and Affordable Medicines
European Public Health Alliance
On social media
🎥 Following live the @EPHA_EU webinar #A2MDialogues welcoming the new #EUpharmaceuticalstrategy as a good starting point to create a future-proof and patient-centred pharmaceutical environment in Europe!— European Alliance for Access to Safe Medicines (@EAASMeds) November 25, 2020
Read the new publication at https://t.co/97FQsyhMuI https://t.co/QsT03f0JhB
Let's make sure that patient, consumer and public health organisations are involved in the implementation of the #EUPharmaStrategy. They have been ignored for the management of the #COVID19 pandemic which brought to inadequate decisions and push-back from EU citizens.— Charlotte Roffiaen (@EU4Ublog) November 25, 2020